Piramal Pharma Limited (BOM:543635)

Piramal Pharma Statistics

Total Valuation

Piramal Pharma has a market cap or net worth of INR 238.81 billion. The enterprise value is 279.88 billion.

Market Cap	238.81B
Enterprise Value	279.88B

Important Dates

The last earnings date was Wednesday, November 5, 2025.

Earnings Date	Nov 5, 2025
Ex-Dividend Date	Jul 16, 2025

Share Statistics

Current Share Class	1.33B
Shares Outstanding	n/a
Shares Change (YoY)	+0.21%
Shares Change (QoQ)	+0.39%
Owned by Insiders (%)	0.20%
Owned by Institutions (%)	23.57%
Float	600.75M

Valuation Ratios

PE Ratio	n/a
Forward PE	101.91
PS Ratio	2.67
PB Ratio	2.96
P/TBV Ratio	6.12
P/FCF Ratio	31.43
P/OCF Ratio	14.95
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 23.36, with an EV/FCF ratio of 36.83.

EV / Earnings	-1,178.95
EV / Sales	3.13
EV / EBITDA	23.36
EV / EBIT	70.80
EV / FCF	36.83

Financial Position

The company has a current ratio of 1.43, with a Debt / Equity ratio of 0.60.

Current Ratio	1.43
Quick Ratio	0.66
Debt / Equity	0.60
Debt / EBITDA	4.29
Debt / FCF	6.38
Interest Coverage	0.88

Financial Efficiency

Return on equity (ROE) is -0.30% and return on invested capital (ROIC) is 1.60%.

Return on Equity (ROE)	-0.30%
Return on Assets (ROA)	1.31%
Return on Invested Capital (ROIC)	1.60%
Return on Capital Employed (ROCE)	2.73%
Revenue Per Employee	16.32M
Profits Per Employee	-43,353
Employee Count	5,476
Asset Turnover	0.57
Inventory Turnover	1.34

Taxes

In the past 12 months, Piramal Pharma has paid 2.38 billion in taxes.

Income Tax	2.38B
Effective Tax Rate	111.07%

Stock Price Statistics

The stock price has decreased by -31.74% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-31.74%
50-Day Moving Average	193.92
200-Day Moving Average	202.16
Relative Strength Index (RSI)	29.03
Average Volume (20 Days)	145,312

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Piramal Pharma had revenue of INR 89.36 billion and -237.40 million in losses. Loss per share was -0.18.

Revenue	89.36B
Gross Profit	54.55B
Operating Income	3.29B
Pretax Income	2.14B
Net Income	-237.40M
EBITDA	10.90B
EBIT	3.29B
Loss Per Share	-0.18

Balance Sheet

The company has 7.44 billion in cash and 48.51 billion in debt, giving a net cash position of -41.07 billion.

Cash & Cash Equivalents	7.44B
Total Debt	48.51B
Net Cash	-41.07B
Net Cash Per Share	n/a
Equity (Book Value)	80.74B
Book Value Per Share	61.03
Working Capital	17.93B

Cash Flow

In the last 12 months, operating cash flow was 15.97 billion and capital expenditures -8.37 billion, giving a free cash flow of 7.60 billion.

Operating Cash Flow	15.97B
Capital Expenditures	-8.37B
Free Cash Flow	7.60B
FCF Per Share	n/a

Margins

Gross margin is 61.05%, with operating and profit margins of 3.68% and -0.27%.

Gross Margin	61.05%
Operating Margin	3.68%
Pretax Margin	2.40%
Profit Margin	-0.27%
EBITDA Margin	12.19%
EBIT Margin	3.68%
FCF Margin	8.50%

Dividends & Yields

This stock pays an annual dividend of 0.14, which amounts to a dividend yield of 0.08%.

Dividend Per Share	0.14
Dividend Yield	0.08%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	n/a
Buyback Yield	-0.21%
Shareholder Yield	-0.13%
Earnings Yield	-0.10%
FCF Yield	3.18%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	5